United States Liquid Biopsy Market Report by Cancer Types, Product, Biomarkers, Application, Sample Types, End User, States and Company Analysis 2026-2034

United States Liquid Biopsy Market Size & Forecast 2026-2034

The United States liquid biopsy market is expected to witness a huge growth rate in the coming years due to the rising demand for non-invasive cancer diagnostic technologies. Liquid biopsy provides accurate, quick, and non-invasive diagnostic results compared to conventional tissue biopsy. United States Liquid Biopsy Market is estimated to reach US$ 4.86 Billion in 2034 from US$ 1.39 Billion in 2025, with a compound annual growth rate of 14.93% during the period of 2026-2034.

United States Liquid Biopsy Market Outlooks

Liquid biopsy is a medical test that is conducted to detect disease-related markers, such as tumor cells, DNA, and other molecules, present in bodily fluids like blood. It is different from the conventional biopsy, as the latter requires surgical procedures to collect tissue samples. In the case of liquid biopsy, only a blood sample is required to detect the genetic and molecular markers. This test has helped doctors detect disease, especially cancer, at an early stage.

Liquid biopsy has become increasingly popular in the USA, as the process is convenient, accurate, and poses no health risks. This test is mostly conducted to detect cancer, treat the disease, and track the recurrence of the disease. Healthcare providers are opting for the liquid biopsy test, as the process can be conducted repeatedly without any surgical procedures. In addition, the increase in the number of cancer cases and the strong healthcare infrastructure are contributing to the growth of the liquid biopsy test.

Growth Drivers of the United States Liquid Biopsy Market

Increasing Prevalence of Cancer and Demand for Early Detection

In the year 2025, it is estimated that in the United States, there will be an estimated number of new cancer cases of 2,041,910 and cancer-related deaths of 618,120. One of the major factors contributing to the growth of the United States liquid biopsy market is the rising prevalence of cancer and the consequent rise in the need for early detection of the disease. Cancer is one of the major reasons for deaths in the country. This, in turn, has created a huge demand for the early detection of cancer. In this context, liquid biopsy helps doctors to detect cancer at an early stage through a simple blood test. This increases the prospects of successful treatment of the disease. Moreover, this method of detection helps to monitor the progress of cancer and its recurrence without going through an invasive process. This method of detection of cancer is preferred by people and doctors due to its safe and accurate nature. As the incidence of cancer increases, the need for liquid biopsy testing also increases, and it is expected that the market for such testing will increase substantially throughout the USA. In 2024, the proportion of the estimated 18.4 million adults eligible for lung cancer screening was 15%, with lower percentages of those aged 50-59 years (11%) compared to those aged 60-69 years (20%) and 70-80 years (18%).

Advancements in Genomic and Molecular Diagnostic Technologies

Technological developments in the field of genomic sequencing and molecular diagnostic techniques have been major factors in the growth of the liquid biopsy market. Advances in technologies like next-generation sequencing and biomarker detection have made liquid biopsy tests more accurate and reliable. This helps in the early detection of genetic mutations and choosing the right treatment for the disease. The constant developments in this field have made liquid biopsy tests sensitive and have expanded their use to other diseases, not just cancer. In addition, the use of artificial intelligence and other sophisticated tools in this field helps in the early detection of diseases. The United States has a well-established biotechnology industry. This helps in the development of sophisticated technologies for the diagnosis of diseases. Therefore, technological developments have made liquid biopsy tests effective and have boosted the growth of the liquid biopsy market. Dec 2025, Roche announces US launch of cobas 6800/8800 systems version 2.0 and software version 2.0.1. The company received US Food and Drug Administration 510(k) clearance for the updated molecular diagnostics platforms earlier this year. The updated systems and software aim to provide enhanced laboratory efficiency through optimized resource allocation, reduced downtime, and increased capacity.

Growing Adoption of Personalized Medicine and Targeted Therapies

The increasing trend of using personalized medicine and target therapies is another major factor that is expected to propel the United States liquid biopsy market. Personalized medicine is a medical practice that aims to tailor medical treatment to the individual information relating to the genetic profile of a patient. Liquid biopsy is a major factor that helps to identify genetic mutations and biomarkers. This helps doctors to choose the most effective treatment for a patient. This helps to improve treatment outcomes and reduce side effects. Pharmaceutical companies and healthcare providers are increasingly using liquid biopsy to practice precision medicine. The increasing trend of using liquid biopsy to improve treatment effectiveness and reduce healthcare costs is another factor that is expected to propel the United States liquid biopsy market. April 2025, Labcorp expansion of its portfolio of precision oncology solutions, which includes Labcorp Plasma Detect, a solution for clinical use to help determine the risk of disease recurrence in Stage III colon cancer patients, and PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from target therapies.

Challenges of the United States Liquid Biopsy Market

High Cost of Testing and Limited Insurance Coverage

One of the major hurdles that the United States liquid biopsy market is likely to face in the near future is the cost of the test, as liquid biopsy tests involve advanced technology, including genomic sequencing, which is a costly procedure. The cost of liquid biopsy tests may act as a hindrance to patients, especially those who do not have adequate insurance coverage. Although liquid biopsy tests provide long-term benefits, the cost of the test may prove to be a major drawback in the near future, as healthcare professionals and patients may hesitate to use liquid biopsy tests due to cost constraints. In addition, the reimbursement of liquid biopsy test costs is in the evolving stage, which may impact the market in the near future. Efforts are being made to reduce the cost of liquid biopsy tests through technological advancements and increased competition in the market.

Regulatory and Clinical Validation Challenges

Regulatory and clinical validation issues are another major challenge that is likely to affect the liquid biopsy market. For example, liquid biopsy tests are subject to strict approval processes to ascertain their accuracy, safety, and reliability. These processes are often expensive and time-consuming, which might affect the development of new products. In addition, liquid biopsy tests are subject to clinical validation to ascertain their effectiveness in different medical applications. This is a major challenge to the adoption of liquid biopsy tests, as healthcare providers need to be convinced of the effectiveness of a diagnostic test before they adopt a new diagnostic tool. Inconsistency in the results of liquid biopsy tests and a lack of standardized testing protocols are also likely to affect the reliability of these tests. For example, regulatory bodies need comprehensive information to approve new liquid biopsy tests, which might be a major challenge to the development of new products. This is a major challenge to the development of new products, as manufacturers need to invest heavily in research and trials to meet these standards.

United States Lung Liquid Biopsy Market

The lung liquid biopsy market in the United States is expanding at a faster rate. This growth can be attributed to the rising incidence rate of lung cancer and the importance of early and precise detection. Liquid biopsy offers the advantage of detecting genetic mutations and cancer-related markers using blood samples, thereby avoiding the use of traditional tissue biopsy. This approach can be applied to lung cancer patients who are not good candidates for invasive procedures. Liquid biopsy can assist doctors in identifying specific genetic mutations, thereby ensuring the choice of drugs for the best outcome. In addition, the disease progression and the effectiveness of the drugs can be closely monitored. Genomic techniques are improving, and the use of precision medicine is on the rise. Healthcare providers are adopting the use of liquid biopsy for the management of cancer, thereby improving the quality of life. As the importance of early detection of cancer increases, the lung liquid biopsy market will grow.

United States Liquid Biopsy Kits & Reagents Market

The liquid biopsy kits and reagents market in the United States is an important segment that provides support to the diagnostic tests and research activities. These kits and reagents are used to obtain, process, and analyze biological samples to identify and measure circulating tumor DNA, cells, and other biomarkers. This market is expected to witness growth due to the increasing need for liquid biopsy tests. Biotechnology firms and diagnostic labs need to use good-quality kits and reagents to obtain reliable and accurate test results. Continuous innovations in molecular diagnostic techniques are enhancing the performance and efficiency of these products. In addition, the increasing focus on investing in cancer research and precision medicine is supporting the growth of this market. The availability of good-quality products is enabling quicker and more accurate diagnosis, which is a major factor in providing better patient care. As the need for liquid biopsy tests is increasing, this segment is expected to witness steady growth.

United States Liquid Biopsy Patient Monitoring Market

The United States of America liquid biopsy patient monitoring market is growing, and this can be attributed to the rising requirement for continuous patient monitoring for individuals with cancer. Liquid biopsy can assist healthcare providers in the continuous monitoring of cancer, identifying the recurrence of the disease, and assessing the response to the treatment. Continuous monitoring can assist healthcare providers in making the required adjustments to the treatment regimen, thereby improving the overall results. Liquid biopsy can assist healthcare providers in the management of advanced and metastatic cancer. Personalized medicine and target-based therapies are on the rise, and this has given the patient monitoring market the impetus to grow. Healthcare providers are opting for the use of liquid biopsy for the continuous monitoring of patients. Healthcare providers can use the results obtained from the use of liquid biopsy to track the progress of the disease. In the future, the use of liquid biopsy can assist healthcare providers in the management of cancer, and this can be attributed to the fact that the management of cancer is becoming more personalized.

United States Liquid Biopsy Circulating Tumor DNA Market

The circulating tumor DNA segment is one of the most prominent segments in the United States liquid biopsy market. Circulating tumor DNA is a fragment of DNA that circulates in the blood and carries vital information regarding cancer and mutations. Circulating tumor DNA plays a vital role in detecting cancer at the initial stage and tracking the progression of cancer. Moreover, it also helps in the selection of targeted therapy. Circulating tumor DNA has gained popularity in the field of liquid biopsies due to the advancement in next-generation sequencing and molecular diagnosis technologies. Circulating tumor DNA plays a vital role in precision medicine. Precision medicine is evolving rapidly, and in this regard, circulating tumor DNA plays a vital role in the liquid biopsy market. Research institutions and biotechnology firms are investing heavily in research on circulating tumor DNA to develop advanced products in this field.

United States Liquid Biopsy Hospitals Market

Hospitals are a major end-user of the liquid biopsy market in the United States, mainly due to their involvement in the diagnosis, treatment, and management of cancer. Liquid biopsy tests are used by hospitals to diagnose, monitor, and manage cancer. Also, the presence of advanced diagnostic equipment and skilled medical practitioners is a major advantage of using liquid biopsy tests in hospitals. Liquid biopsy helps hospitals offer quicker and more comfortable diagnostic tests to patients. Moreover, liquid biopsy is becoming a regular part of cancer treatment and management in hospitals. There is a partnership between hospitals, research institutions, and biotechnology companies that is positively impacting the development of this diagnostic technique. In addition, the increasing number of cancer patients and the need for advanced diagnostic tests are creating a high demand for liquid biopsy tests. As hospitals are adopting more and more of this diagnostic technique, the liquid biopsy market is expected to grow steadily in the United States.

California Liquid Biopsy Market

California is considered one of the prominent liquid biopsy markets in the USA, considering the high level of development of the local healthcare infrastructure and the local biotechnological sector. There are a number of local biotechnological companies, research centers, and diagnostic laboratories that are engaged in the development of advanced genomic medicine. In addition, the high incidence of cancer cases and the growing awareness of the importance of early disease detection are also fueling the growth of the local market for liquid biopsy testing services. In California, the local healthcare sector is increasingly embracing the use of liquid biopsy for the diagnosis, treatment, and prevention of cancer. In addition, the local emphasis on the development of advanced healthcare solutions and the use of technology for the development of precision medicine are also fueling the growth of the local market for liquid biopsy testing services.

New York Liquid Biopsy Market

The New York market for liquid biopsy is witnessing steady growth owing to the rising demand for advanced cancer diagnostic technologies. New York has a well-developed healthcare infrastructure and has some of the best hospitals, diagnostic centers, and cancer treatment facilities. Liquid biopsy has been found to be an effective method for cancer detection and monitoring. Furthermore, the rising incidence of cancer and awareness about liquid biopsy as a non-invasive cancer detection method are driving the market. New York has many research centers and medical universities that are contributing to the development of liquid biopsy technologies. Precision medicine has been adopted by healthcare providers to ensure better treatment outcomes and patient care. Advanced laboratory facilities and skilled professionals are also driving the market. New investment in healthcare innovation and the demand for personalized medicine solutions are expected to contribute to the growth of the New York liquid biopsy market.

New Jersey Liquid Biopsy Market

The liquid biopsy market in New Jersey is growing due to the presence of pharmaceutical and biotechnology industries in the state. There are a number of pharmaceutical companies, research centers, and diagnostic centers in the state that are contributing to the growth of the liquid biopsy market. The liquid biopsy market in New Jersey is growing due to the rising prevalence of cancer in the state and the increasing awareness among people about the importance of early disease diagnosis. Healthcare providers in the state are using liquid biopsy to improve cancer diagnosis and treatment. Furthermore, the state also has advanced healthcare facilities that are contributing to the growth of the liquid biopsy market. Pharmaceutical companies in the state are partnering with healthcare providers to improve liquid biopsy technology. Furthermore, the state is also improving the quality of healthcare and precision medicine, which is also contributing to the growth of the liquid biopsy market in the state.

Washington Liquid Biopsy Market

The market for liquid biopsy in Washington is witnessing steady growth due to the rising acceptance of advanced diagnostic technologies. Additionally, the rising awareness about precision medicine is also driving the liquid biopsy market in the state. Washington has a well-developed healthcare system with modern hospital infrastructure and research centers. Furthermore, the rising occurrence of cancer and the need for minimally invasive diagnostic tools are also driving the liquid biopsy market in the state. Healthcare providers in Washington are increasingly using liquid biopsy to detect cancer in patients. Moreover, the presence of prominent research centers and biotechnology firms in the state is also driving the liquid biopsy market. Additionally, the rising investment in the state's healthcare system is also driving the liquid biopsy market in Washington. People in the state prefer liquid biopsy due to its convenience, accuracy, and lower risks. Furthermore, the rising acceptance of precision medicine is also driving the liquid biopsy market in the state.

Market Segments

Cancer Types

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancer

Products

• Kits & Reagents
• Platforms & Instruments
• Services

Application

• Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

Biomarkers

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVs)

Sample Types

• Blood
• Urine
• Others

End-Users

• Hospitals & Laboratories
• Governments & Academic Research Centers

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories Inc.
• Biocept, Inc.
• Biocartis
• Myriad Genetics, Inc.
• Exact Sciences (Genomic Health)
• NeoGenomics Laboratories
• Quest Diagnostic Inc.